6533b830fe1ef96bd1296e54

RESEARCH PRODUCT

PI3K/AKT Activation and Response in Phase IB: AKT Inhibitor GDC-0068 with Docetaxel (D) Or MFOLFOX6 (F) in Refractory Solid Tumors

Guillem ArgilesYibing YanJ-c. SoriaSteven J. IsakoffDesamparados RodaAndrés CervantesRaymond D. MengJohanna C. BendellJoaquin MateoAntoine HollebecqueL. R. MolifeL. De Mattos-arruda

subject

OncologySolid tumourmedicine.medical_specialtybusiness.industryHematologyAkt inhibitorUniversity hospitalInstitut Gustave RoussyOncologyDocetaxelInternal medicinemedicineGeneral hospitalbusinessProtein kinase BPI3K/AKT/mTOR pathwaymedicine.drug

description

R. Meng1, L. R. Molife2, L. de Mattos-Arruda3, A. Hollebecque4, S. J. Isakoff5, D. Roda6, Y. Yan1, A. Cervantes6, J. C. Soria4, J. Mateo2, G. Argiles3, J. C. Bendell7 Genentech, South San Francisco, CA, USA, Institute of Cancer Research/ Royal Marsden Hospital, Sutton, United Kingdom, Vall d’Hebron University Hospital, Barcelona, Spain, Institut Gustave Roussy, Villejuif, France, Massachusetts General Hospital, Boston, MA, USA, Institute of Health Research INCLIVA, University of Valenica, Valencia, Spain, Sarah Cannon Research Institute, Nashville, TN, USA

yearjournalcountryeditionlanguage
2013-03-01Annals of Oncology
https://doi.org/10.1093/annonc/mdt048.3